Advertisement

Advertisement

hepatobiliary cancer

Poorer Overall Survival With Sunitinib vs Sorafenib in Advanced Hepatocellular Cancer

In an open-label phase III superiority/noninferiority trial reported in Journal of Clinical Oncology by Ann-Lii Cheng, MD, of National Taiwan University Hospital in Taipei, sunitinib (Sutent) was associated with significantly poorer overall survival compared with sorafenib (Nexavar) in a population ...

hepatobiliary cancer

Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma

Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...

hepatobiliary cancer

Survival Trend With Palliative FOLFOX4 vs Doxorubicin in Asian Patients With Advanced Hepatocellular Carcinoma

In a study reported in Journal of Clinical Oncology, Shukui Qin, MD, of People’s Liberation Army Cancer Centre, Bayi Hospital, in Nanjing, and colleagues compared FOLFOX4 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) with doxorubicin as palliative chemotherapy in patients with ...

hepatobiliary cancer

No Overall Survival Benefit With Brivanib in Advanced Hepatocellular Carcinoma Patients After Sorafenib Failure or Intolerance

The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...

hepatobiliary cancer

First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma

The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...

Advertisement

Advertisement

Advertisement